

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/511,980	
			Filing Date	April 7, 2005	
			First Named Inventor	Amalfitano et al.	
			Art Unit	1633	
			Examiner Name	Fereydown Ghotb Sajjadi	
Sheet	1	of	3	Attorney Docket Number	180/151 PCT/US

(Use as many sheets as necessary)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Allen et al., "Identification and Elimination of Replication-Competent Adeno-Associated Virus (AAV) That Can Arise by Nonhomologous Recombination during AAV Vector Production," Journal of Virology. Vol. 71, No. 9 pgs. 6816-6822 (1997).	
	2	Conway et al., "High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type 1 vector expressing AAV-2 Rep and Cap," Gene Therapy. Vol. 6 pgs. 986-993 (1999).	
	3	Coulie et al., "A New Gene Coding for a Differentiation Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas," Journal of Experimental Medicine. Vol. 180 pgs. 35-42 (1994).	
	4	Daly et al., "Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease," PNAS. Vol. 96 pgs. 2296-2300 (1999).	
	5	Franco et al., "Evasion of Immune Response to Introduced Human Acid α -Glucosidase by Liver-Restricted Expression in Glycogen Storage Disease Type II," Molecular Therapy. Vol. 12, No. 5 pgs. 876-884 (2005).	
	6	Gorman et al., "Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs," PNAS. Vol. 95 pgs. 4929-4934 (1998).	
	7	Hoefsloot et al., "Primary structure and processing of lysosomal α -glucosidase; homology with the intestinal sucrase - isomaltase complex," The EMBO Journal. Vol. 7, No. 6 pgs. 1697-1704 (1988).	
	8	Inoue, N., and Russell, D.W., "Packaging Cells Based on Inducible Gene Amplification for the Production of Adeno-Associated Virus Vectors," Journal of Virology. Vol. 72, No. 9 pgs. 7024-7031 (1998).	
	9	Jung et al., "Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice," PNAS. Vol. 98, No. 5 pgs. 2676-2681 (2001).	
	10	Kawakami et al., "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor," PNAS. Vol. 91 pgs. 3515-3519 (1994).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/511,980
Filing Date	April 7, 2005
First Named Inventor	Amalfitano et al.
Art Unit	1633
Examiner Name	Fereydoun Ghotb Sajjadi
Attorney Docket Number	180/151 PCT/AUS

Sheet	2	of	3
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	Kawakami et al., "Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating Lymphocytes," The Journal of Experimental Medicine. Vol. 180 pgs. 347-352 (1994).	
	12	Kishnani et al., "Canine Model and Genomic Structural Organization of Glycogen Storage Disease Type Ia (GSD Ia)," Vet. Pathol. Vol. 38 pgs. 83-91 (2001).	
	13	Matsushita et al., "Adeno-associated virus vectors can be efficiently produced without helper virus," Gene Therapy. Vol. 5 pgs. 938-945 (1998).	
	14	Raben et al., "Targeted Disruption of the Acid α -Glucosidase Gene in Mice Causes an Illness with Critical Features of Both Infantile and Adult Human Glycogen Storage Disease Type II," The Journal of Biological Chemistry. Vol. 273, No. 30 pgs. 19086-19092 (1998).	
	15	Recchia et al., "Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector," PNAS. Vol. 96 pgs. 2615-2620 (1999).	
	16	Robbins et al., "Recognition of Tyrosinase by Tumor-Infiltrating Lymphocytes from a Patient Responding to Immunotherapy," Cancer Research. Vol. 54 pgs. 3124-3126 (1994).	
	17	Rosenberg, "A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens," Immunity. Vol. 10 pgs. 281-287 (1999).	
	18	Rouet et al., "A Potent Enhance Made of Clustered Liver-specific Elements in the Transcription Control Sequences of Human α 1-Microglobulin/Bikunin Gene," The Journal of Biological Chemistry. Vol. 267, No. 29 pgs. 20765-20773 (1992).	
	19	Snyder et al., "Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors," Nature Medicine. Vol. 5, No. 1 pgs. 64-70 (1999).	
	20	Tinsley et al., "Amelioration of the dystrophic phenotype of <i>mdx</i> mice using a truncated utrophin transgene," Letters to Nature. Vol. 384 pgs. 349-353(1996).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 606. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/511,980	
			Filing Date	April 7, 2005	
			First Named Inventor	Amalfitano et al.	
			Art Unit	1633	
			Examiner Name	Fereydzan Ghotb Sajjadi	
Sheet	3	of	3	Attorney Docket Number	180/151 PCT/US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite ¹ No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	21	Van der Ploeg et al., "Intravenous Administration of Phosphorylated Acid α -Glucosidase Leads to Uptake of Enzyme in Heart and Skeletal Muscle of Mice," Journal of Clinical Investigation. Vol. 87 pgs. 513-518 (1991).		
	22	Vincent et al., "Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene," Nature Genetics. Vol. 5 pgs. 130-134 (1993).		
	23	Wang et al., "Sustained correction of bleeding disorder in hemophilia B mice by gene therapy," PNAS. Vol. 96 pgs. 3906-3910 (1999).		
	24	Wisselaar et al., "Structural and Functional Changes of Lysosomal Acid α -Glucosidase during Intracellular Transport and Maturation," The Journal of Biological Chemistry. Vol. 268, No. 3 pgs. 2223-2231 (1993).		
	25	Xiao et al., "Adeno-Associated Virus as a Vector for Liver-Directed Gene Therapy," Journal of Virology. Vol. 72, No. 12 pgs. 10222-10226 (1998).		
	26	Yang et al., "Characterization of Cell Lines That Inducibly Express the Adeno-Associated Virus Rep Proteins," Journal of Virology. Vol. 68, No. 8 pgs. 4847-4856 (1994).		
	27	Zolotukhin et al., "Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield," Gene Therapy. Vol. 6 pgs. 973-985 (1999).		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.58. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.